In a recent legal development, several patients in the United States have filed a lawsuit against the manufacturers of Ozempic and Mounjaro, alleging that the drugs caused them to suffer vision loss. The plaintiffs claim that the medications, which are part of the glucagon‑like peptide‑1 (GLP‑1) class, have led to serious ocular complications.
The case highlights growing concerns about the safety profile of GLP‑1 therapies, which are widely prescribed for type‑2 diabetes and increasingly used for weight management. While the lawsuit focuses on U.S. patients, the issue has attracted attention in other markets.
In Nigeria, GLP‑1 injections have become more readily available, prompting a Premium Times investigation that uncovered a surge in online sales of these drugs without prescriptions or medical oversight. The report noted that many consumers were purchasing the medications directly from e‑commerce platforms, raising questions about regulation and patient safety.
Health authorities in Nigeria have warned that unregulated access to GLP‑1 medicines can lead to misuse and adverse effects, echoing the concerns raised by the U.S. lawsuit. The situation underscores the need for stricter controls on prescription drugs in both developed and emerging markets.
<small>Source: Premium Times Nigeria — read the original story there.</small>
